Neurocrine Biosciences Inc.
NBIX | NASDAQ
$145.85
-$0.25 (-0.17%)
Nov 2, 2026, 12:41 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 2.86B | 2.36B | 1.89B | 1.49B | 1.13B | 1.05B |
Cost of Revenue | 52.1M | 34M | 39.7M | 23.2M | 14.3M | 10.1M |
Gross Profit | 2.81B | 2.32B | 1.85B | 1.47B | 1.12B | 1.04B |
Operating Income | 619.1M | 570.5M | 250.9M | 249M | 102.5M | 163M |
Interest Income | 90.3M | 91M | n/a | 11.2M | n/a | n/a |
Pretax Income | 705.4M | 486M | 332.1M | 213.9M | 101.4M | 106.7M |
Net Income | 478.6M | 341.3M | 249.7M | 154.5M | 89.6M | 407.3M |
Selling & General & Admin | 1.16B | 1.01B | 887.6M | 752.7M | 583.3M | 433.3M |
Research & Development | 1.02B | 731.1M | 565M | 463.8M | 328.1M | 275M |
Other Expenses | 17.4M | 12.5M | 143.9M | n/a | 105.3M | 164.5M |
Operating Expenses | 2.19B | 1.75B | 1.6B | 1.22B | 1.02B | 872.8M |
Interest Expense | n/a | 126.6M | 4.6M | 7.1M | 25.8M | 32.8M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.24B | 1.78B | 1.64B | 1.24B | 1.03B | 882.9M |
Income Tax Expense | 226.8M | 144.7M | 82.4M | 59.4M | 11.8M | -300.6M |
Shares Outstanding (Basic) | 99.5M | 100.4M | 97.7M | 95.8M | 94.6M | 93.1M |
Shares Outstanding (Diluted) | 102.5M | 103.7M | 101M | 98.9M | 97.9M | 97.8M |
EPS (Basic) | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 | 4.37 |
EPS (Diluted) | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 |
EBITDA | 666.6M | 639.7M | 416.1M | 236.6M | 138.1M | 148.1M |
EBIT | 636.5M | 612.6M | 394.8M | 221M | 127.2M | 139.5M |
Depreciation & Amortization | 30.1M | 27.1M | 21.3M | 15.6M | 10.9M | 8.6M |
Add to Watchlist
Select watchlists to add or remove NBIX